VaxSyna

VaxSyna is a biotechnology company that develops a modular, patented vaccine platform designed to address infectious diseases and other global health challenges. The company's technology utilizes self-assembling, higher-order antibody complexes that display multiple antigens on a human IgG backbone. This configuration triggers an immune response through Fc-receptor binding and crosslinking, enabling the development of highly immunogenic vaccines that can function without the need for chemical adjuvants. The platform is engineered to be easily modifiable for different target antigens and is manufactured using a transient, plant-based expression system in Nicotiana benthamiana, which allows for rapid, high-yield production of recombinant proteins.

The company focuses on creating vaccines that are thermally stable and cost-effective, with the goal of improving vaccine accessibility in low-to-middle-income countries. VaxSyna’s lead product candidates include prophylactic and therapeutic vaccines targeting HPV and herpes simplex virus. By utilizing optimized plant expression systems, the company aims to significantly lower manufacturing costs compared to current market standards. VaxSyna, which was founded in 2020 and is headquartered in the United States, has utilized federal grant funding to advance its research, including proof-of-concept studies to characterize its broad-spectrum HPV cancer vaccine candidate.